The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2016 | History of approvals for proteasome inhibitors bortezomib, carfilzomib and ixazomib
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium provides an overview of the approval of proteasome inhibitors in relapsed/refractory multiple myeloma (MM) since 2003. Prof Delforge first discusses bortezomib, which was first approved by the US Food and Drug Administration (FDA) in 2003 and later, was approved for the use as upfront therapy in Europe and the US. Based on the success story of bortezomib, second generation proteasome inhibitors such as carfilzomib in combination with lenalidomide and dexamethasone, have been approved. Ixazomib, an oral proteasome inhibitor, has also been approved.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
